MARINOL CAPSULE

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

DRONABINOL

Dostupno od:

ABBOTT LABORATORIES, LIMITED

ATC koda:

A04AD10

INN (International ime):

DRONABINOL

Doziranje:

5MG

Farmaceutski oblik:

CAPSULE

Sastav:

DRONABINOL 5MG

Administracija rute:

ORAL

Jedinice u paketu:

60

Tip recepta:

Prescription

Područje terapije:

MISCELLANEOUS ANTIEMETICS

Proizvod sažetak:

Active ingredient group (AIG) number: 0116400001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2012-02-24

Svojstava lijeka

PRODUCT MONOGRAPH
N
MARINOL
®
dronabinol (delta-9-tetrahydrocannabinol; Δ
9
-THC)
2.5 mg and 5 mg capsules
Antiemetic
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
DATE OF PREPARATION:
January 1, 2011
Control No.: 143312
Registered Trade-mark Unimed Pharmaceuticals Inc., Licensed use by
Abbott Laboratories, Limited, Saint-Laurent,
Quebec, H4S 1Z1
_N_
_MARINOL_
_® _
_ _
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY OF PRODUCT
INFORMATION..........................................................................3
INDICATIONS AND CLINICAL
USE......................................................................................3
CONTRAINDICATIONS
...........................................................................................................4
WARNINGS AND
PRECAUTIONS..........................................................................................5
DRUG ABUSE AND DEPENDENCE
.......................................................................................6
ADVERSE REACTIONS
...........................................................................................................8
DRUG
INTERACTIONS..........................................................................................................10
DOSAGE AND
ADMINISTRATION......................................................................................12
OVERDOSAGE
........................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
....................................................................14
STORAGE AND
STABILITY..................................................................................................17
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................................17
PART II: SCIENTIFIC INFORMATION
......................................................................